<DOC>
	<DOCNO>NCT01188265</DOCNO>
	<brief_summary>Dextromethorphan report afford neuroprotection dopaminergic neuron protective effect inflammation-related neuron damage . These anti-inflammatory neuroprotective effect dextromethorphan would suggest potential clinical benefit dextromethorphan add-on therapy valproate bipolar disorder patient . This hypothesis base finding mood stabilizer report neuroprotective release neurotrophic factor GDNF astroglia . Thus , combination treatment mood stabilizer dextromethorphan might improve therapeutic efficacy bipolar disorder patient .</brief_summary>
	<brief_title>Add-on Dextromethorphan Bipolar Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Male female patient age ≧18 ≦65 year . 2 . A diagnosis bipolar I II disorder accord DSMIV criterion make specialist psychiatry . 3 . A total HDRS score least 18 YMRS score least 14 screen . 4 . Signed informed consent patient legal representative 5 . Patient reliable caregiver expect ensure acceptable compliance visit attendance duration study . 1 . Women childbearing potential use adequate contraception per investigator judgment willing comply contraception duration study . 2 . Females pregnant nursing . 3 . Patient receive dextromethorphan , selective cyclo oxygenase 2 ( Cox2 ) inhibitor , antiinflammatory medication within 1 week prior first dose doubleblind medication . 4 . AxisI DSMIV diagnosis bipolar I II disorder . 5 . Current evidence uncontrolled and/or clinically significant medical condition ( e.g. , cardiac , hepatic renal failure ) , judgment investigator , would compromise patient safety preclude study participation . 6 . History intolerance valproate dextromethorphan Cox2 inhibitor . 7 . History sensitivity reaction ( e.g. , urticaria , angioedema , bronchospasm , severe rhinitis , anaphylactic shock ) precipitate dextromethorphan . 8 . Patient receive electroconvulsive therapy ( ECT ) within 4 week prior first dose doubleblind medication . 9 . Diagnosis treatment esophageal , gastric , pyloric channel , duodenal ulceration relate complication ( bleed and/or perforation ) within 30 day prior receive first dose doubleblind medication . 10 . Inclusion another bipolar disorder study study another indication psychotropic 's within last 30 day prior start study . 11 . Increase total SGOT , SGPT , BUN creatinine 3X ULN ( upper limit normal ) . 12 . History idiopathic druginduced agranulocytosis . 13 . Substancerelated disorder within 6 month prior study start , borderline personality disorder , schizophrenia , major psychiatric disorder define DSMIV criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>